期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 908, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2021.174346
关键词
Autophagy; Apoptosis; Gefitinib; FOXO; Lung cancer; Epidermal growth factor receptor
资金
- National Natural Science Foundation of China [81874315, 81302798]
- CAMS Innovation Fund for Medical Sciences [2019I2M5-074]
- Program for the Ministry of Education Peptide Drugs Innovation Team [IRT_15R27]
- Science and Technology Project of Gansu Province [18JR2RA031]
Non-small cell lung cancer (NSCLC) is the most common cancer in the world, and Gefitinib has been shown to be effective in treating NSCLC. However, innate and acquired resistance present challenges in therapy. Inhibition of autophagy is considered a promising strategy to overcome resistance.
Non-small cell lung cancer (NSCLC) is the most common cancer in the world. Gefitinib, an inhibitor of EGFR tyrosine kinase, is highly effective in treating NSCLC patients with activating EGFR mutations (L858R or Ex19del). However, despite excellent disease control with gefitinib therapy, innate resistance and inevitable acquired resistance represent immense challenges in NSCLC therapy. Gefitinib potently induces cytoprotective autophagy, which has been implied to contribute to both innate and acquired resistance to gefitinib in NSCLC cells. Currently, abrogation of autophagy is considered a promising strategy for NSCLC therapy. In the present study, YC-1, an inhibitor of HIF-1 alpha, was first found to significantly inhibit the autophagy induced by gefitinib by disrupting the fusion of autophagosomes and lysosomes and thereby enhancing the proapoptotic effect of gefitinib in gefitinib-resistant NSCLC cells. Furthermore, the combinational anti-autophagic and pro-apoptotic effect of gefitinib and YC-1 was demonstrated to be associated with an enhanced of forkhead box protein O1 (FOXO1) transcriptional activity which resulted from an increase in the p-FOXO1 protein level in gefitinib-resistant NSCLC cells. Our data suggest that inhibition of autophagy by targeting FOXO1 may be a feasible therapeutic strategy to overcome both innate and acquired resistance to EGFR-TKIs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据